

Ruiz Boy S¹, Alberdi Lema C¹, Lizondo T¹, Carro I¹, Martin M¹, Tuset M¹, Hernández J², Amaro R³,
Fernández Avilés F⁴, Cardozo C⁵, Soy Muner D¹

¹Pharmacy Service. Division of Medicines. Hospital Clínic de Barcelona - Universitat de Barcelona (HCB-UB);

²Internal Medicine Service- Autoimmune Diseases Unit. HCB-UB; ³Pneumology Service. HCB-UB;

⁴Hematology Service. HCB-UB; ⁵Internal Medicine Service- Infectious Diseases Unit. HCB-UB

Background and Importance

- Human immunoglobulins (HI) are essential for the treatment of primary immunodeficiency (PI). They are also used for other conditions. Some of them do not have strong evidence or have therapeutic alternatives. Given the current shortage of HI, careful review of its indication is warranted.

Aim and Objectives

- To describe the use of HI of an adult population treated in a tertiary university hospital.
- To identify those indications with a low level of evidence according to the national guidelines.

Materials and Methods


- Observation retrospective study. No intervention. All patients who received HI between 1 January – 31 December 2022, were included.
- Data was obtained from electronic medical records.

Results


Total grams consumed: 104.786 g	
Intravenous HI: 83.5 %	Nº patients: 432
Inpatient administration: 31.0%	Female gender: 52.3%
Treatment ≥3 months: 48.4%	Median Age (IQR): 60 (45.0-71.3)
HI naïve patients: 48.8%	Median Body Mass Index (IQR): 25.12 (22.0-28.6)

IQR: interquartil range

% HI consumption according to prescribing physician specialty



% HI consumption according to indication



Conclusion and Relevance

- HI are widely used by multiple specialties.
- HI for low-evidence indications are used in a low, but still significant, percentage. These uses must be reviewed by a multidisciplinary team to optimize the prescription of HI.

